Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06275126 · ClinicalTrials.gov registry record · NA
Optimizing Surgical Decisions in Young Adults With Breast Cancer
A NA study of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- NA
- Development phase
- 800
- Enrollment target
- 4
- Study locations
NCT06275126 is a NA study of Breast Cancer Stage II and Breast Cancer Stage III that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 800 participants, above the 146-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (448% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT06275126, a NA study of Breast Cancer Stage II and Breast Cancer Stage III, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions. Participants will complete surveys approximately within 1 week of the surgical consult and approximately 6 months after surgery. Patients who receive neoadjuvant chemotherapy will also be surveyed after the completion of neoadjuvant treatment but prior to surgery. Some patients will be invited for an interview after their surgery as part of the evaluation. A subset of patients/surgeons will also have their surgical consultation audio-recorded.
Conditions Studied
Interventions
- OTHER CONSYDER decision aid
Study Locations (4)
Connecticut
- Yale Cancer Center - New Haven
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Weill Cornell Medicine - New York
North Carolina
- Duke Cancer Institute - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2024-03-13 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06275126
The ClinicalTrials.gov registry entry for NCT06275126 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 146-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (448% higher). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer Stage II appearing as the primary indexed condition, and to 1 intervention - of which CONSYDER decision aid is the first listed.
NCT06275126 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Connecticut, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06275126 about?
NCT06275126 is a clinical study titled "Optimizing Surgical Decisions in Young Adults With Breast Cancer". The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful informatio...
What is the current status of trial NCT06275126?
This trial is currently recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2024-03-13. Estimated completion is 2027-08-31.
What conditions does trial NCT06275126 study?
This clinical trial studies the following conditions: Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I, Breast Cancer Stage 0.
What interventions are being tested in trial NCT06275126?
The interventions under investigation include: CONSYDER decision aid (OTHER).
Who is sponsoring clinical trial NCT06275126?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06275126 being conducted?
This trial has 4 study locations across Connecticut, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Stage II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
RECRUITING · NA
-
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
RECRUITING · NA
-
A Study of Language Interpretation Solutions for People With Breast Cancer
RECRUITING · NA
-
A Study of the TheraBionic P1 Device in Breast Cancer
RECRUITING · NA
-
Abbreviated MBCT for Depression in Older African American/Black Breast Cancer Survivors
ACTIVE NOT RECRUITING · NA
-
Taking AIM at Breast Cancer
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.